Clinical Study of CLDN18.2 PET/CT for Noninvasive Diagnosis of Gastric and Pancreatic Cancer

Launched by YIHUI GUAN · Jan 3, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to diagnose gastric and pancreatic cancers using two imaging agents, \[18F\]F-H3RESCA-3A12 and \[68Ga\]Ga-NOTA-3A12. These agents will help create detailed images that can show if cancer has spread in these organs, without the need for invasive procedures like surgery. This study aims to find out how effective and safe these imaging methods are, which could lead to better and more precise diagnoses for patients with metastatic gastric and pancreatic cancers.

To participate in this trial, you need to be between 18 and 65 years old and have been diagnosed with gastric or pancreatic cancer through a biopsy or surgery. You also need to be able to give consent, either personally or through a legal guardian. If you have serious kidney or liver issues, have undergone recent major surgery, or are currently involved in other clinical trials, you may not be eligible. Participants can expect to undergo noninvasive imaging tests and help researchers learn more about how to diagnose these cancers accurately. This could ultimately improve the way doctors identify and treat gastric and pancreatic cancers in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) Age between 18 and 65 years old, gender is not limited. (2) Patients with gastric or pancreatic cancer confirmed by puncture or surgical pathology.
• • (3) Written informed consent signed by the subject or his/her legal guardian or caregiver.
• • (4) Willingness and ability to cooperate with all programs of this study.
• Exclusion Criteria:
• • - (1) Severe hepatic or renal insufficiency; (2) Targeted therapy before radiotherapy or PET/CT scan. (3)Renal function: serum creatinine less than or equal to the upper limit of the normal range;Liver function: bilirubin, AST(SGOT)/ALT(SGPT) less than or equal to the upper limit of the normal range.
• • (4) History of serious surgery in the last month. (5) Those who have participated in other clinical trials during the same period.